TACSTD2 and posterior cortical atrophy: Having shown that the GSE1 and TACSTD2 expression profiles influence the therapy responses and clinical outcomes in patients with PCa, we performed immunohistochemical staining of the samples from our in-house PCa cohort (n = 56).